The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Sokolova M.A.
Gematologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Moskva
Turkina A.G.
Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva
Melikjan A.L.
GBOU VPO «Pervyj MGMU im. I.M. Sechenova» Minzdrava Rossii, Moskva
Sudarikov A.B.
Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva
Treglazova S.A.
National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
Shukhov O.A.
National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
Gemdzhyan E.G.
National Research Center for Hematology, Moscow, Russia
Abdullaev A.O.
FGBU "Gematologicheskiĭ nauchnyĭ tsentr" Minzdrava Rossii, Moskva
Kovrigina A.M.
Nauchno-klinicheskoe otdelenie gematologicheskoĭ khirurgii Gematologicheskogo nauchnogo tsentra Minzdrava RF, Moskva
Misiurin A.V.
Federal'nyĭ nauchno-klinicheskiĭ tsentr detskoĭ gematologii, onkologii i immunologii im. Dmitriia Rogacheva Minzdrava Rossii, Moskva
Pliskunova Yu.V.
National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
Ivanova V.L.
S.P. Botkin City Clinical Hospital, Moscow, Russia
Moiseeva T.N.
FGBU "Gematologicheskiĭ nauchnyĭ tsentr" Minzdrava Rossii, Moskva
Efficiency of interferon therapy in patients with essential thrombocythemia or polycythemia vera
Journal: Therapeutic Archive. 2016;88(12): 69‑77
Views: 11599
Downloaded: 795
To cite this article:
Sokolova MA, Turkina AG, Melikjan AL, et al. . Efficiency of interferon therapy in patients with essential thrombocythemia or polycythemia vera. Therapeutic Archive.
2016;88(12):69‑77. (In Russ.)
https://doi.org/10.17116/terarkh2016881269-77
Aim. To evaluate the efficiency of interferon (IFN) therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Subjects and methods. A total of 61 patients (41 with ET and 20 with PV) were examined. Prior to study enrolment, 44 (72%) patients with ET or PV received one or other therapy (aspirin was not taken into account). The mean Jak2V617F mutant allele at baseline was 23% (6—54%) in the patients with ET and 40% (11—88%) in those with PV. The median time from diagnosis to enrollment was 49 months. Results. The paper presents the clinical and molecular findings of long-term INF-α therapy in patients with ET or PV. The median follow-up was 52 months. Recombinant IFN-α2 showed its ability to induce complete hematologic remission (ET (76%), PV (70%)) and a complete molecular response. 22 (69%) out of 32 patients were noted to have a smaller number of cells with the Jak2V617F mutation. In the patients with PV and in those with ET, the relative reduction in the proportion of cells with the Jak2V617F mutant gene averaged 85% and 56% of the baseline values, respectively. There was a reduction in the proportion of cells expressing the Jak2V617F mutation in both the ET (from 12 to 2.2%; p=0.001) and PV (from 32.7% to 3.2%) groups (р=0.001). Ten (31%) patients achieved a deep molecular remission (≤2% Jak2V617F allele); among them, 5 patients were not found to have Jak2V617F mutation. The obtained molecular response remained in 7 of the 10 patients untreated for 11 to 86 months. The long-term treatment with IFN-α led to normalization of the morphological pattern of bone marrow in 5 of the 7 PV or ET patients. Conclusion. Significant molecular remissions achieved by therapy with recombinant interferon-α2 confirm the appropriateness of this treatment option in in the majority of patients with ET or PV.
Authors:
Sokolova M.A.
Gematologicheskiĭ nauchnyĭ tsentr Minzdrava RF, Moskva
Turkina A.G.
Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva
Melikjan A.L.
GBOU VPO «Pervyj MGMU im. I.M. Sechenova» Minzdrava Rossii, Moskva
Sudarikov A.B.
Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii, Moskva
Treglazova S.A.
National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
Shukhov O.A.
National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
Gemdzhyan E.G.
National Research Center for Hematology, Moscow, Russia
Abdullaev A.O.
FGBU "Gematologicheskiĭ nauchnyĭ tsentr" Minzdrava Rossii, Moskva
Kovrigina A.M.
Nauchno-klinicheskoe otdelenie gematologicheskoĭ khirurgii Gematologicheskogo nauchnogo tsentra Minzdrava RF, Moskva
Misiurin A.V.
Federal'nyĭ nauchno-klinicheskiĭ tsentr detskoĭ gematologii, onkologii i immunologii im. Dmitriia Rogacheva Minzdrava Rossii, Moskva
Pliskunova Yu.V.
National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia
Ivanova V.L.
S.P. Botkin City Clinical Hospital, Moscow, Russia
Moiseeva T.N.
FGBU "Gematologicheskiĭ nauchnyĭ tsentr" Minzdrava Rossii, Moskva
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.